High altitude, A natural research laboratory for the study of cardiovascular physiology and pathophysiology

Progress in Cardiovascular Diseases

Volumn 52, Issue 6, 2010, Pages 451-455

  Scherrer, Urs ^a   Allemann, Yves ^a   Jayet, Pierre Yves ^a   Rexhaj, Emrush ^a   Sartori, Claudio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cardiovascular physiology; High altitude; Pathophysiology

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; NITRIC OXIDE; OXYGEN;

ADRENERGIC SYSTEM; ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; HORMONE INHIBITION; HUMAN; HYPOXIA; LUNG EDEMA; NONHUMAN; OXIDATIVE STRESS; PATENT FORAMEN OVALE; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RISK ASSESSMENT;

ALTITUDE; ALTITUDE SICKNESS; ANIMALS; BIOMEDICAL RESEARCH; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FORAMEN OVALE, PATENT; GLUCOCORTICOIDS; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; OXIDATIVE STRESS; PHOSPHODIESTERASE INHIBITORS; PULMONARY EDEMA; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77952194755     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.02.002     Document Type: Article

References (45)

1. Bärtsch P., Maggiorini M., Ritter M., et al. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991, 325:1284-1289.
2. Scherrer U., Vollenweider L., Delabays A., et al. Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 1996, 334:624-629.
3. Allemann Y., Sartori C., Lepori M., et al. Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol 2000, 279:H2013-H2016.
4. Maggiorini M., Melot C., Pierre S., et al. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 2001, 103:2078-2083.
5. Maggiorini M. High altitude-induced pulmonary oedema. Cardiovasc Res 2006, 72:41-50.
6. Duplain H., Sartori C., Lepori M., et al. Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med 2000, 162:221-224.
7. Sartori C., Vollenweider L., Loffler B.M., et al. Exaggerated endothelin release in high-altitude pulmonary edema. Circulation 1999, 99:2665-2668.
8. Sartori C., Allemann Y., Scherrer U. Pathogenesis of pulmonary edema: learning from high-altitude pulmonary edema. Respir Physiol Neurobiol 2007, 159:338-349.
9. Berger M.M., Hesse C., Dehnert C., et al. Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am J Respir Crit Care Med 2005, 172:763-767.
10. Sartori C., Allemann Y., Trueb L., et al. Augmented vasoreactivity in adult life associated with perinatal vascular insult. Lancet 1999, 353:2205-2207.
11. Hakim T.S., Mortola J.P. Pulmonary vascular resistance in adult rats exposed to hypoxia in the neonatal period. Can J Physiol Pharmacol 1990, 68:419-424.
12. Scherrer U., Turini P., Thalmann S., et al. Pulmonary hypertension in high-altitude dwellers: novel mechanisms, unsuspected predisposing factors. Adv Exp Med Biol 2006, 588:277-291.
13. Maggiorini M., Brunner-La Rocca H.P., Peth S., et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006, 145:497-506.
14. Sartori C., Allemann Y., Duplain H., et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002, 346:1631-1636.
15. Sartori C., Rimoldi S.F., Scherrer U. Lung fluid movements in hypoxia. Prog Cardiovasc Dis 2010, 52:493-499.
16. Scherrer U., Rexhaj E., Jayet P.-Y., Allemann Y., Sartori C. New insights in the pathogenesis of high-altitude pulmonary edema. Prog Cardiovasc Dis 2010, 52:485-492.
17. Egli M., Duplain H., Lepori M., et al. Defective respiratory amiloride-sensitive sodium transport predisposes to pulmonary oedema and delays its resolution in mice. J Physiol 2004, 560:857-865.
18. Perkins G.D., McAuley D.F., Thickett D.R., et al. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006, 173:281-287.
19. Licker M., Tschopp J.M., Robert J., et al. Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest 2008, 133:845-852.
20. Busch T., Bartsch P., Pappert D., et al. Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am J Respir Crit Care Med 2001, 163:368-373.
21. Beall C.M. Tibetan and Andean patterns of adaptation to high-altitude hypoxia. Hum Biol 2000, 72:201-228.
22. Hoit B.D., Dalton N.D., Erzurum S.C., et al. Nitric oxide and cardiopulmonary hemodynamics in Tibetan highlanders. J Appl Physiol 2005, 99:1796-1801.
23. Leuchte H.H., Schwaiblmair M., Baumgartner R.A., et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004, 125:580-586.
24. Palmieri E.A., Affuso F., Fazio S., et al. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004, 141:743-744.
25. Sayin T., Ozenci M. Sustained long-term benefit of sildenafil in primary pulmonary hypertension. Acta Cardiol 2007, 62:47-49.
26. Barbera J.A., Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009, 69:1153-1171.
27. Schwab M., Jayet P.Y., Stuber T., et al. Pulmonary-artery pressure and exhaled nitric oxide in Bolivian and Caucasian high altitude dwellers. High Alt Med Biol 2008, 9:295-299.
28. Stuber T., Sartori C., Salmon C.S., et al. Respiratory nitric oxide and pulmonary artery pressure in children of aymara and European ancestry at high altitude. Chest 2008, 134:996-1000.
29. Chen H.I. Hemodynamic mechanisms of neurogenic pulmonary edema. Biol Signals 1995, 4:186-192.
30. Dauber I.M., Weil J.V. Lung injury edema in dogs: influence of sympathetic ablation. J Clin Invest 1983, 72:1977-1986.
31. Duplain H., Vollenweider L., Delabays A., et al. Augmented sympathetic activation during short-term hypoxia and high-altitude exposure in subjects susceptible to high altitude pulmonary edema. Circulation 1999, 99:1713-1718.
32. Randin D., Vollenweider P., Tappy L., et al. Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med 1995, 332:1733-1737.
33. Scherrer U., Vollenweider P., Randin D., et al. Suppression of insulin induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation 1993, 88:388-394.
34. Owlya R., Vollenweider L., Trueb L., et al. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 1997, 96:3897-3903.
35. Allemann Y., Hutter D., Lipp E., et al. Patent foramen ovale and high-altitude pulmonary edema. JAMA 2006, 296:2954-2958.
36. Johansson M.C., Eriksson P., Peker Y., et al. The influence of patent foramen ovale on oxygen desaturation in obstructive sleep apnoea. Eur Respir J 2007, 29:149-155.
37. Torti S.R., Billinger M., Schwerzmann M., et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J 2004, 25:1014-1020.
38. Brennan L.A., Steinhorn R.H., Wedgwood S., et al. Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase. Circ Res 2003, 92:683-691.
39. Hoshikawa Y., Ono S., Suzuki S., et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001, 90:1299-1306.
40. Dosek A., Ohno H., Acs Z., et al. High altitude and oxidative stress. Respir Physiol Neurobiol 2007, 158:128-131.
41. Carratelli M., Porcaro L., Ruscica M., et al. Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res 2001, 21:79-84.
42. de Haan J.B., Susil B., Pritchard M., et al. An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the "gene dosage effect" hypothesis. J Neural Transm Suppl 2003, 67-83.
43. Iannello R.C., Crack P.J., de Haan J.B., et al. Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm Suppl 1999, 57:257-267.
44. Bras A., Monteiro C., Rueff J. Oxidative stress in trisomy 21. A possible role in cataractogenesis. Ophthalmic Paediatr Genet 1989, 10:271-277.
45. Durmowicz A.G. Pulmonary edema in 6 children with Down syndrome during travel to moderate altitudes. Pediatrics 2001, 108:443-447.